Sarfaraz Niazi, PhD (University of Illinois at Chicago), discusses the impacts of the Inflation Reduction Act—President Biden’s historic new prescription drug law under which drug companies will pay rebates to Medicare when their prescription drug prices increase faster than the rate of inflation for certain drugs—on the use of generics and biosimilars. Also, Sami Khella, MD (University of Pennsylvania), talks about the phase 3 NEURO-TTRansform Study, which produced promising results for eplontersen in treating hereditary transthyretin-mediated amyloid polyneuropathy.
Let us know what you thought of this week’s episode on Twitter: @physicianswkly
Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com!
Thanks for listening!